Results Hepatic packing with drainage and blood pressure control were done. Patient received Low Molecular Weight Heparin and Aspirin and improved after 13 days without bleeding. Conclusions Spontaneous hepatic rupture is a rare, life-threatening presentation of APAS that warrants timely diagnosis and effective control of haemorrhage to prevent maternal and fetal mortality. Early initiation of anticoagulation is both safe and effective in preventing APAS complications. Aspirin should be initiated to prevent future thrombosis and pregnancy loss.

62

STUDY OF CLINICAL UTILITY OF ANTIBODIES TO PHOSPHATIDYLSERINE/PROTHROMBIN COMPLEX IN INDIAN PATIENTS

A Ganapati*, R Goel, J Kabeerdoss, M Gowri, J Mathew, D Danda. *Christian Medical College – Vellore, Rheumatology, Vellore, India*

10.1136/lupus-2017-000215.62

Background and aims To explore utility of Antibodies to Phosphatidylserine/Prothrombin Complex (aPSPT), in Indian Antiphospholipid Syndrome (APS) patients.

Methods Data of 372 subjects whose sera was tested for aPSPT by ELISA (AESUKU,GERMANY), was retrospectively analysed. Performance of various APLs was compared using non-parametric tests. To ascertain additional utility of aPSPT, patients with suspected APS were categorised into 2 groups i. e. i) those with any one of criteria antibodies positive ii) those with any one APL positivity including anti- PSPT positivity.

Results In 46 patients of APS, 38 (82.60%) had thrombotic events (21 arterial, 26 venous) and 11 (23.91%) had obstetric events. Lupus anticoagulant was present in 37/46 (80.43%), anticardiolipin antibody in 19/46 (41.33%), aPSPT in 17/46 (36.95%), anti-β2glycoprotein1 (β2GP1) IgG and IgM in 13/46 (28.26%) and 7/46 (15.21%) patients of APS respectively. aPSPT tested positive in 9/60 (15%) patients with seronegative APS (SNAPS). aPSPT did not differ from other criteria APLs in any clinical parameter except compared to those with IgM B2GP-1 positivity. aPSPT was numerically more sensitive and specific than IgM B2GP1 for thrombotic, non-criteria events but less sensitive for detecting obstetric events (Table 2). Inclusion of aPSPT test in patients with suspected APS increased

Abstract 62 Tabel 1 Showing the categorization of Study subjects into patients and controls

Type of Subjects	Number	Sub-categorization	
Total Number of Subjects	372	Female - 331	
		Male -41	
Definite APS (satisfying revised Sapporo criteria)	46	Primary -20	
		Secondary-26	
Controls	326	Patients with seronegative APS (SNAPS)- 60	
		Connective Tissue Disease controls-146	
		Obstetric Controls- 107	
		Healthy Controls -13	

Abstract 62 Tabel 2 Comparision of sensitivity and specificity of aPSPT and IqM anti-β2GP1 in definite APS patients

Definite APS patients	Anti PSPT positive		IgM Anti-β2GPI antibody positive	
	Sensitivity	Specificity	Sensitivity	Specificity
Obstetric Events	27.3%	38.5%	45.5%	11.5%
Arterial Events	38.1%	32%	9.5%	24%
Venous Events	38.5%	30%	11.5%	25%
Non criteria manifestations	50%	29.4%	16.7%	17.6%

sensitivity marginally but with concomitant decrease ir specificity.

Conclusions In our study, aPSPT was third most common antibody in APS patients, displaying higher sensitivity and specificity in comparison to IgM anti- $\beta 2$ GP1 for all APS manifestations except obstetric ones. SNAPS patients may test positive for aPSPT, thus endorsing its inclusion in classification criteria of APS.

63

RITUXIMAB: IN THE MANAGEMENT OF ANTIPHOSPHOLIPID ANTIBODIES ASSOCIATED CHOREA IN A CHILD WITH LUPUS

¹A Jindal^{*}, ¹P Vignesh, ¹A Gupta, ²J Ahluwalia, ¹D Suri, ¹A Rawat, ¹S Singh. ¹PGIMER, Paediatrics, chandigarh, India; ²PGIMER, haematology, chandigarh, India

10.1136/lupus-2017-000215.63

Background and aims Neuropsychiatric manifestations are noted in 50.94% of children with lupus. Chorea, a non-thrombotic complication associated with antiphospholipid antibodies (APLA), is seen in 4% cases.

Aim- To describe the clinical course of a child with lupus who had chorea on follow up and was treated with rituximab Methods A 10 year old girl presented with spastic quadriparesis, fever, weight loss, alopecia, oral ulcers, anaemia and thrombocytopenia. Antinuclear antibody was 4+ diffuse pattern; and anti-dsDNA titres were 220.25 IU/ml (normal <55 IU/ml). T2 weighted magnetic resonance imaging (MRI) brain and spine showed multiple foci of increased signal intensity in bilateral corona radiata and centrum semiovale. She also had positive lupus anticoagulant and elevated anticardiolipin antibody titres. She received steroids, azathioprine, anticoagulants and aspirin, and showed remarkable improvement. Five years later, she was admitted with multiple joint pains and foot drop related to mononeuritis multiplex. She developed seizures and MRI brain showed diffuse cerebral atrophy with T2/FLAIR white matter hyperintensities. At 18 years of age, she presented with chorea and MRI showed periventricular T2/FLAIR hyperintensities. She responded to intravenous pulses of methylprednisolone and cyclophosphamide. Three years later, she again had similar choreiform movements with aggressive behaviour, which did not respond to haloperidol, steroids and warfarin. At this point of time, she was administered 3 doses of rituximab (500 mg/m² at one weekly interval).

LUPUS 2017;**4**(Suppl 1):A1–A227